As the first wave of gene therapy programs continue to progress into and through the clinic, attention has turned to finding and optimizing the next generation of improved vector candidates, with significant investment pouring into improving the safety, efficacy, and predictability of delivery platforms.

In this setting, the 4th Next Generation Gene Therapy Vectors Summit returned as the only industry-focused event covering the latest advances and innovations in vector development for gene therapies, uniting R&D and business development leaders to advance cutting-edge delivery platforms into the clinic.

60+ biopharma, service provider, and academic pioneers untied to share data-driven examples of how they have improved the new wave of viral gene therapy vectors, and shared highly translatable insights into the latest disruptive non-viral platforms. Attendees were able to leverage the latest data and collectively brainstorm solutions to the key challenges facing their vector platforms.

If you continue to work towards the end goal of developing safe, predictable, cost-effective, scalable, and tissue-specific platforms that can deliver to a diverse range of cell types, join us next year for the world’s leading capsid and payload optimization forum.